SCHEMBL1966690

SCHEMBL1966690

COc1ccc(C=NC2CCC(O)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.49
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
TSHR P16473 1/20 0.45
GRIN2D O15399 2/20 0.45
GRIN3B O60391 2/20 0.45
GRIN1 Q05586 2/20 0.45
GRIN2A Q12879 2/20 0.45
GRIN2B Q13224 2/20 0.45
GRIN2C Q14957 2/20 0.45
GRIN3A Q8TCU5 2/20 0.45
S100B P04271 1/20 0.44
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAOA P21397 1/20 0.42
CHRNA7 P36544 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13446559 1.00 RAB9A (0.49) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL1966687 1.00 RAB9A (0.49) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL31351777 0.92 KMT2A (0.49) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL31351734 0.92 KMT2A (0.49) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL1129964 0.85 KMT2A (0.59) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL1129966 0.85 KMT2A (0.59) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL19233521 0.83 KMT2A (0.62) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL1969379 0.82 KMT2A (0.45) RAB9AKMT2AALDH1A1GRIN2DGRIN3B
SCHEMBL15961339 0.76 ALDH1A1 (0.37) RAB9AKMT2AALDH1A1LMNATSHR
SCHEMBL13446456 0.76 ALDH1A1 (0.37) RAB9AKMT2AALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334301-B1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO SA (CH) 2018-02-14 EP disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 US disclosed
EP-2334301-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS Merck Serono SA (CH) 2011-06-22 EP disclosed
WO-2010028116-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS AURKC, AURKA, AURKB RAB9A 2966/4885KMT2A 1335/4885ALDH1A1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.